title: Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.
abstract: Highly active antiretroviral therapy (HAART) can suppress HIV-1 replication and normalize the chronic immune activation associated with infection, but restoration of naïve CD4+ T cell populations is slow and usually incomplete for reasons that have yet to be determined. We tested the hypothesis that damage to the lymphoid tissue (LT) fibroblastic reticular cell (FRC) network contributes to naïve T cell loss in HIV-1 infection by restricting access to critical factors required for T cell survival. We show that collagen deposition and progressive loss of the FRC network in LTs prior to treatment restrict both access to and a major source of the survival factor interleukin-7 (IL-7). As a consequence, apoptosis within naïve T cell populations increases significantly, resulting in progressive depletion of both naïve CD4+ and CD8+ T cell populations. We further show that the extent of loss of the FRC network and collagen deposition predict the extent of restoration of the naïve T cell population after 6 month of HAART, and that restoration of FRC networks correlates with the stage of disease at which the therapy is initiated. Because restoration of the FRC network and reconstitution of naïve T cell populations are only optimal when therapy is initiated in the early/acute stage of infection, our findings strongly suggest that HAART should be initiated as soon as possible. Moreover, our findings also point to the potential use of adjunctive anti-fibrotic therapies to avert or moderate the pathological consequences of LT fibrosis, thereby improving immune reconstitution.
authors.affiliation: Department of Microbiology, Medical School, University of Minnesota, Minneapolis, Minnesota, United States of America.
authors.forename: Ming
authors.initials: M
authors.lastname: Zeng
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Southern
authors.forename: Cavan S
authors.initials: CS
authors.lastname: Reilly
authors.forename: Greg J
authors.initials: GJ
authors.lastname: Beilman
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Chipman
authors.forename: Timothy W
authors.initials: TW
authors.lastname: Schacker
authors.forename: Ashley T
authors.initials: AT
authors.lastname: Haase
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D005355:Fibrosis; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D015497:HIV-1; D006801:Humans; D015851:Interleukin-7 / Q000276:immunology; D008221:Lymphoid Tissue / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: C508605:IL7 protein, human; D015851:Interleukin-7